As most Stage IV-patients receive systemic therapy prior to the resection of LM, the validation of our findings in humans is difficult, as chemotherapy may prevent or delay intravasation of tumor cells, as well as priming of a premetastatic niche, for example by VEGF-inhibition. The gene discussed is VEGFA; the disease is lymphangioma.